Peptide therapeutic for cancer - Bristol-Myers Squibb/PeptiDream

Drug Profile

Peptide therapeutic for cancer - Bristol-Myers Squibb/PeptiDream

Alternative Names: Program 1 - Bristol-Myers Squibb/PeptiDream

Latest Information Update: 29 Jun 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; PeptiDream
  • Developer Bristol-Myers Squibb
  • Class Macrocyclic compounds; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 15 Jun 2016 Phase-I clinical trials in Cancer in USA (unspecified route)
  • 17 Sep 2013 Bristol-Myers Squibb and PeptiDream extend their therapeutic peptides collaboration for a further 2 years
  • 15 Feb 2013 Bristol-Myers Squibb and PeptiDream extend their therapeutic peptides collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top